Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Mild increases in intact and C-terminal FGF23 as well as 1,25(OH)2 vitamin D were noted (Table 1).

Source: Biochemical Parameters. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Cortical thickness (Ct.Th µm) was also quantified using the OsteoMeasure; values from both cortices were obtained and data from both patients were pooled.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Jansen's Disease: Bone Abnormalities Beyond Chondrodysplasia

Study design awaiting verification · The Journal of Clinical Endocrinology and Metabolism · 2025

Original publication title

Jansen's Disease: Bone Abnormalities Beyond Chondrodysplasia

Renata C Pereira; Anne M Delany; Monica Reyes; Barbara Gales; Harald Jüppner; Isidro B Salusky

© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The H223R-PTH1R mutation in patients with JMC leads to bone structural irregularities, hypomineralization, abnormal osteocyte morphology, and altered expression of osteocyte-derived proteins. These findings underscore the multifaceted impact of the mutant PTH1R on bone physiology and focus attention on the osteocyte as a cellular target for therapeutic intervention. Whether normalizing gene expression in osteocytes is possible and can improve bone health in patients with JMC remains to be seen. Assessment of osteocyte morphology and function may provide novel diagnostic endpoints for future clinical trials with JMC therapeutics.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

This study aimed to assess changes in bone microarchitecture, bone formation, and bone protein expression in 2 pediatric patients with JMC harboring the H223R-PTHR1 mutation.

Source: Objective

Abstract: What methods does the paper describe?

Bone histomorphometry, immunohistochemistry, and histologic analyses were conducted on iliac crest biopsy samples from 2 male siblings affected by JMC (ages 6 and 8 years) and 9 healthy control males of similar age, with normal kidney function.

Source: Methods

Abstract: Context

Jansen metaphyseal chondrodysplasia (JMC) is an ultra-rare autosomal dominant disease that is caused by heterozygous, activating PTH1R mutations resulting in PTH: and PTHrP-independent hypercalcemia and hypercalciuria, leading to nephrocalcinosis and impaired renal function later in life. The activated PTH1R plays critical roles in mineral ion homeostasis and bone lengthening, as well as bone formation and resorption. Currently, little is known about bone turnover markers and bone histomorphometric changes in JMC patients.

Source: Context

Abstract: Results

Both patients with JMC displayed irregular bone architecture, increased osteoid, and a prolonged osteoid maturation process. While trabecular volume remained normal, immunohistochemical analysis demonstrated increased in PTH1R expression in both osteoblasts and fibroblastic cells on the bone surface. Cortical bone displayed areas of intense osteoclast activity and scattered marrow fibrosis. Remarkably, osteocytes in samples from patients with JMC had osteoid buildup within their lacunae and canaliculi that were both shorter and less abundant. DMP1 immunohistochemistry highlighted the abnormal canalicular network in patients.

FGF23 staining in osteocytes was enhanced while sclerostin was diminished.

Source: Results

Abstract: Conclusion

The H223R-PTH1R mutation in patients with JMC leads to bone structural irregularities, hypomineralization, abnormal osteocyte morphology, and altered expression of osteocyte-derived proteins. These findings underscore the multifaceted impact of the mutant PTH1R on bone physiology and focus attention on the osteocyte as a cellular target for therapeutic intervention. Whether normalizing gene expression in osteocytes is possible and can improve bone health in patients with JMC remains to be seen. Assessment of osteocyte morphology and function may provide novel diagnostic endpoints for future clinical trials with JMC therapeutics.

Source: Conclusion
Authors’ abstract

Abstract

Context

Jansen metaphyseal chondrodysplasia (JMC) is an ultra-rare autosomal dominant disease that is caused by heterozygous, activating PTH1R mutations resulting in PTH: and PTHrP-independent hypercalcemia and hypercalciuria, leading to nephrocalcinosis and impaired renal function later in life. The activated PTH1R plays critical roles in mineral ion homeostasis and bone lengthening, as well as bone formation and resorption. Currently, little is known about bone turnover markers and bone histomorphometric changes in JMC patients.

Objective

This study aimed to assess changes in bone microarchitecture, bone formation, and bone protein expression in 2 pediatric patients with JMC harboring the H223R-PTHR1 mutation.

Methods

Bone histomorphometry, immunohistochemistry, and histologic analyses were conducted on iliac crest biopsy samples from 2 male siblings affected by JMC (ages 6 and 8 years) and 9 healthy control males of similar age, with normal kidney function.

Results

Both patients with JMC displayed irregular bone architecture, increased osteoid, and a prolonged osteoid maturation process. While trabecular volume remained normal, immunohistochemical analysis demonstrated increased in PTH1R expression in both osteoblasts and fibroblastic cells on the bone surface. Cortical bone displayed areas of intense osteoclast activity and scattered marrow fibrosis. Remarkably, osteocytes in samples from patients with JMC had osteoid buildup within their lacunae and canaliculi that were both shorter and less abundant. DMP1 immunohistochemistry highlighted the abnormal canalicular network in patients.

FGF23 staining in osteocytes was enhanced while sclerostin was diminished.

Conclusion

The H223R-PTH1R mutation in patients with JMC leads to bone structural irregularities, hypomineralization, abnormal osteocyte morphology, and altered expression of osteocyte-derived proteins. These findings underscore the multifaceted impact of the mutant PTH1R on bone physiology and focus attention on the osteocyte as a cellular target for therapeutic intervention. Whether normalizing gene expression in osteocytes is possible and can improve bone health in patients with JMC remains to be seen. Assessment of osteocyte morphology and function may provide novel diagnostic endpoints for future clinical trials with JMC therapeutics.

Publication and source details

Original title: Jansen's Disease: Bone Abnormalities Beyond Chondrodysplasia

Renata C Pereira; Anne M Delany; Monica Reyes; Barbara Gales; Harald Jüppner; Isidro B Salusky

The Journal of Clinical Endocrinology and Metabolism · 2025

Correspondence: Renata Pereira, PhD, Division of Pediatric Nephrology, David Geffen School of Medicine, UCLA, 650 Charles E Young DR S A2-379, Los Angeles, CA 90095-8347, USA. Email: rpereira@mednet.ucla.edu; or Harald Jueppner, MD, Endocrine Unit, Department of Medicine and Pediatric Nephrology Unit, Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, MA 02114, USA. Email: HJUEPPNER@mgh.harvard.edu.© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms. NIH10.13039/501100012264 R01DK113039UO1DK122013 Connie Frank Bone Laboratory

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:10:40.301274+00:00

DOI: 10.1210/clinem/dgaf097 · PMC12448618